Respiratory

Obstructive sleep apnea: outpatient diagnosis and CPAP

Clinical Overview and When to Suspect OSA

— Loud habitual snoring, witnessed apneas, gasping/choking arousals

— Excessive daytime sleepiness, unrefreshing sleep, morning headaches, nocturia (≥2 voids/night unexplained), poor concentration

— Resistant hypertension (BP uncontrolled on ≥3 agents including a diuretic) — OSA present in 70–80%

— New-onset atrial fibrillation, nocturnal arrhythmias, recurrent AF after cardioversion/ablation

— Type 2 diabetes with poor control, obesity (BMI ≥30), metabolic syndrome

— Heart failure with preserved or reduced EF, pulmonary hypertension, stroke/TIA

Obstructive sleep apnea (OSA) is repetitive upper airway collapse during sleep producing apneas/hypopneas, oxyhemoglobin desaturation, sympathetic surges, and sleep fragmentation.

Prevalence in US adults: ~15–30% of men, 10–15% of women; markedly underdiagnosed in primary care.

Suspect OSA in any adult with:

Anatomic/risk modifiers: large neck circumference (>17 in men, >16 in women), retrognathia, macroglossia, tonsillar hypertrophy, nasal obstruction, male sex, postmenopausal status, family history, Black/Asian ancestry (craniofacial), hypothyroidism, acromegaly, chronic opioid use.

Board pearl: USPSTF (2022) found insufficient evidence to screen asymptomatic adults for OSA — so on Step 3, you do not screen universally; you case-find in symptomatic or high-risk patients (HTN, AF, CHF, DM, stroke, occupational drivers).

Why it matters for Step 3: untreated OSA increases all-cause mortality, MVAs (2–3×), perioperative complications, and worsens HTN, AF, glycemic control, and depression — making it a high-yield ambulatory, perioperative, and transitions-of-care topic.

Step 3 management: when a patient with resistant HTN, nocturnal AF, or refractory daytime sleepiness walks into clinic, OSA should be on your top-3 differential and you should move toward objective sleep testing rather than empiric lifestyle counseling alone.

Presentation Patterns and Key History

— Loud snoring most nights (sensitivity ~80–90%)

— Witnessed apneas or gasping by bed partner (most specific clinical feature)

— Excessive daytime sleepiness despite ≥7 hours in bed

— Morning headache (hypercapnia/vasodilation), dry mouth on waking, drenching night sweats

— Nocturia, GERD at night, decreased libido/erectile dysfunction

— Mood disturbance, irritability, poor memory, MVAs or near-misses

— Restless sleep, frequent position changes, partner sleeps in another room

— STOP-BANG (≥3 = intermediate risk, ≥5 = high risk): Snore loud, Tired, Observed apnea, Pressure (HTN), BMI >35, Age >50, Neck >40 cm, Gender male

— Epworth Sleepiness Scale (ESS): ≥11 abnormal; quantifies sleepiness but does not diagnose OSA

— Berlin questionnaire, NoSAS — less commonly tested

— Commercial drivers (CDL), pilots, heavy machinery operators, train engineers

— Ask about MVAs, drowsy driving, near-misses — has implications for DOT certification

— Resistant HTN, AF, HFpEF, stroke, DM, CKD, polycythemia, pulmonary HTN

— Medication review: opioids, benzodiazepines, alcohol — worsen OSA and central apneas

Core symptom triad (ask explicitly — patients underreport):

Other supportive history:

Screening tools to know:

Occupational and safety history is mandatory on Step 3:

Comorbidity-driven history:

Key distinction: OSA = preserved respiratory effort against a closed airway; central sleep apnea (CSA) = absent effort (seen in CHF with Cheyne-Stokes, opioid use, high altitude, stroke). History of decompensated CHF with crescendo-decrescendo breathing → think CSA, not OSA.

Board pearl: A STOP-BANG ≥5 plus an ESS ≥11 in an obese hypertensive man is a near-lock OSA stem — proceed to objective sleep testing, do not start CPAP empirically.

Physical Exam Findings and Hemodynamic Assessment

— Obesity (BMI ≥30), central adiposity, neck circumference >17 in (M) / >16 in (W)

— Elevated BP, particularly nocturnal non-dipping or resistant pattern

— Resting SpO₂ usually normal awake (abnormal suggests overlap with COPD/obesity hypoventilation)

— Retrognathia, micrognathia, high-arched palate, overjet

— Macroglossia (scalloped tongue edges), enlarged tonsils (Friedman/Mallampati grading)

— Modified Mallampati III–IV (only soft palate/hard palate visible) predicts OSA

— Nasal obstruction: septal deviation, turbinate hypertrophy, polyps

— Crowded oropharynx, low-hanging uvula, lateral pharyngeal wall thickness

— Loud P2, RV heave, peripheral edema → pulmonary HTN/cor pulmonale

— S3, JVD, rales → CHF (consider overlap)

— Wheezing/prolonged expiration → COPD overlap ("overlap syndrome")

— Acanthosis nigricans (insulin resistance), acromegalic features, myxedematous facies (hypothyroidism)

— Office BP often masks nocturnal HTN; ambulatory BP monitoring reveals non-dipping

— Polycythemia (Hb >16.5 men, >16 women) on CBC suggests chronic hypoxemia

— Elevated bicarbonate (HCO₃⁻ ≥27) on BMP suggests chronic CO₂ retention → consider obesity hypoventilation syndrome (OHS)

General/vitals:

Craniofacial and upper airway:

Cardiopulmonary signs suggesting end-organ effects:

Skin and endocrine clues:

Hemodynamic assessment relevant to OSA:

Key distinction: OSA alone = normal awake PaCO₂; OHS = BMI ≥30 + awake PaCO₂ ≥45 mmHg without other cause — OHS has higher mortality and often needs BiPAP, not CPAP.

Step 3 management: in a sleepy obese patient with HCO₃⁻ 32 and SpO₂ 91% awake, get an ABG before sleep testing — you may be dealing with OHS, which changes therapy and disposition.

Board pearl: Mallampati and neck circumference together outperform BMI alone for predicting moderate-to-severe OSA on physical exam.

Diagnostic Workup — Initial Labs, Screening, and Risk Tools

— CBC: secondary erythrocytosis from chronic hypoxemia

— BMP: elevated HCO₃⁻ as a clue to chronic hypoventilation/OHS

— HbA1c, fasting lipids: high comorbidity with metabolic syndrome

— TSH: hypothyroidism worsens OSA and can mimic fatigue

— Ferritin if restless legs symptoms coexist

— ECG: AF, LVH, RV strain, bradyarrhythmias during sleep

— Echocardiogram if pulmonary HTN, HF, or unexplained RV findings suspected

— Consider ambulatory BP monitoring in resistant HTN to document non-dipping pattern

— ABG if HCO₃⁻ ≥27, SpO₂ <94% awake, or BMI ≥40 → evaluate for OHS

— Not routine; consider lateral neck/cephalometric imaging only if surgical evaluation planned

— Chest imaging only if overlap COPD or HF suspected

— STOP-BANG ≥3 + symptoms → proceed to sleep testing

— High pretest probability (STOP-BANG ≥5, witnessed apneas, daytime sleepiness, no significant cardiopulmonary disease) → home sleep apnea test (HSAT) is acceptable first-line

— Low-to-intermediate probability, significant comorbidity (CHF, COPD, neuromuscular disease, suspected CSA/OHS, opioid use), or negative HSAT despite high suspicion → in-lab polysomnography (PSG)

OSA is a clinical + sleep-study diagnosis; routine labs do not diagnose it but identify comorbidities and complications.

Baseline outpatient labs to order when OSA is suspected:

Cardiopulmonary baseline:

Imaging:

Pretest probability tools drive testing choice:

Board pearl: A negative HSAT in a patient with high clinical suspicion does not rule out OSA — order in-lab PSG. HSAT tends to underestimate AHI because total sleep time is assumed, not measured.

Step 3 management: Don't order an HSAT in a patient with CHF, suspected central apnea, hypoventilation, or significant lung disease — go straight to in-lab PSG.

Diagnostic Workup — Sleep Studies and Severity Grading

— Records EEG, EOG, EMG (sleep staging), airflow, respiratory effort (thoracoabdominal belts), SpO₂, ECG, body position, leg EMG

— Allows differentiation of obstructive vs central vs mixed apneas, scoring of RERAs, titration of PAP

— Measures airflow, effort, SpO₂, heart rate; no EEG → uses recording time, not sleep time

— Validated only for uncomplicated adults with high pretest probability

— Not for: significant cardiopulmonary disease, suspected CSA/OHS, neuromuscular disease, chronic opioid use, prior stroke, or pediatric patients

— Apnea–Hypopnea Index (AHI) = (apneas + hypopneas)/hour of sleep

— Respiratory Disturbance Index (RDI) = AHI + RERAs/hour

— Oxygen Desaturation Index (ODI), nadir SpO₂, time SpO₂ <90% (T90)

— Mild: AHI 5–14

— Moderate: AHI 15–29

— Severe: AHI ≥30

— AHI ≥15 alone is diagnostic regardless of symptoms

— AHI 5–14 plus symptoms (sleepiness, fatigue, insomnia) or comorbidity (HTN, AF, CAD, stroke, CHF, T2DM, mood disorder) is diagnostic

— Split-night PSG: diagnostic first half, CPAP titration second half if AHI ≥40 (or ≥20 with severe desaturations) in first 2 hours

— Auto-titrating PAP (APAP) at home is acceptable for uncomplicated moderate-severe OSA without significant cardiopulmonary disease

In-lab polysomnography (PSG) is the gold standard:

Home sleep apnea test (HSAT) — type III portable monitor:

Key metrics:

Adult severity (AASM):

Diagnostic thresholds:

Titration strategies:

Key distinction: Central apneas have absent respiratory effort on belts; obstructive have continued effort against a closed airway — this drives therapy choice (CPAP vs ASV vs BiPAP-ST).

Board pearl: If the stem gives AHI 22 in an obese hypertensive with daytime sleepiness — that's moderate OSA, diagnosis confirmed, initiate CPAP.

Risk Stratification and First-Line Management Logic

— Any moderate or severe OSA (AHI ≥15) → treat

— Mild OSA (AHI 5–14) → treat if symptomatic or comorbid HTN, AF, CAD, stroke, HF, DM, or occupational risk

— Weight loss: 10% weight reduction can reduce AHI ~25–30%; bariatric surgery for BMI ≥35 with comorbidity

— Avoid alcohol within 3 hours of bed, avoid benzodiazepines/opioids/sedating muscle relaxants

— Positional therapy for documented positional OSA (supine-only events, AHI <15 non-supine)

— Sleep hygiene, treat nasal obstruction (intranasal steroids, septoplasty)

— Smoking cessation

— Mandibular advancement device (MAD) — fit by qualified dentist; best for mild-moderate OSA or CPAP-intolerant

— Hypoglossal nerve stimulation (Inspire) — for moderate-severe OSA, BMI <32–35, CPAP-intolerant, AHI 15–65, non-concentric palatal collapse on DISE

— Upper airway surgery (UPPP, maxillomandibular advancement, tonsillectomy) — selected anatomic candidates

— Tracheostomy — last resort for life-threatening OSA refractory to all else

— Solriamfetol, modafinil/armodafinil, pitolisant — for residual excessive daytime sleepiness despite adequate CPAP, not as primary therapy

— Treat coexisting hypothyroidism, allergic rhinitis

Treatment decision driven by severity + symptoms + comorbidity, not AHI alone:

First-line therapy for moderate-severe OSA: positive airway pressure (PAP), typically CPAP.

Behavioral/lifestyle measures — adjunctive, not sole therapy for moderate-severe:

Alternatives when CPAP fails or is refused:

Pharmacologic adjuncts (limited role):

Step 3 management: Moderate-severe OSA in an adult → start CPAP first + counsel on weight loss + alcohol/sedative avoidance + driving safety. Reserve MAD/surgery/Inspire for intolerance or failure.

Board pearl: GLP-1 agonists (semaglutide, tirzepatide) now have OSA data — tirzepatide (SURMOUNT-OSA) reduced AHI substantially in obese adults; expect this on future exams as adjunct to PAP.

Pharmacotherapy and CPAP Initiation — First-Line "Drug" Regimen

— Device: CPAP (single pressure) vs APAP (auto-adjusting within a range, e.g., 5–15 cm H₂O) vs BiPAP (separate IPAP/EPAP — used when high pressures, CO₂ retention, or CPAP-intolerant)

— Pressure: derived from in-lab titration or APAP 90th-percentile pressure; typical range 5–15 cm H₂O

— Mask interface: nasal pillows, nasal mask, or full-face (oronasal); mouth breathers and high pressures often need full-face

— Heated humidification to reduce dryness; ramp feature for comfort at initiation

— Expiratory pressure relief (EPR/C-Flex) for comfort

— Nasal saline, intranasal steroids for congestion

— Chin strap for mouth leak with nasal mask

— Mask refitting if leaks, skin breakdown, or claustrophobia

— ≥4 hours/night on ≥70% of nights over 30 consecutive days within first 90 days

— Documented clinical benefit at follow-up visit between days 31–90

— Failure to meet adherence → CPAP discontinued by payer; consider alternatives

— Dry mouth/nose → humidification, full-face mask, treat nasal congestion

— Aerophagia → reduce pressure, switch to BiPAP, head elevation

— Mask leak/skin breakdown → refit, alternate interface, barrier dressings

— Claustrophobia → desensitization, nasal pillows, CBT

— Persistent sleepiness despite use → check adherence data, residual AHI, sleep duration; consider wake-promoting agent

CPAP is the "drug" of OSA — Step 3 expects you to know initiation, settings, and troubleshooting.

Prescription elements:

Adjuncts:

Adherence definition (CMS/Medicare for continued coverage):

Common early problems (and fixes):

Step 3 management: Patient returns at 4 weeks using CPAP 2.5 h/night — do not abandon therapy. Troubleshoot mask, pressure, humidification, and behavioral barriers; consider switching to APAP or BiPAP before declaring CPAP failure.

Board pearl: CPAP improves BP modestly (2–3 mmHg average, more in resistant HTN), reduces AF recurrence post-ablation, improves daytime sleepiness, and improves quality of life — but SAVE and RICCADSA trials did not show CPAP reduces major cardiovascular events in established CVD, largely due to poor adherence.

CPAP Alternatives and Procedural Options

— Custom-fit by trained dentist; titrated over weeks

— Best for mild-to-moderate OSA, positional OSA, or CPAP-intolerant patients with moderate-severe disease

— Contraindications: inadequate dentition, severe TMJ disease, severe OSA with significant desaturation (relative)

— Side effects: TMJ pain, tooth movement, bite changes, hypersalivation

— Requires follow-up sleep study to confirm efficacy

— Implanted device stimulates CN XII during inspiration → tongue protrusion

— Indications (FDA): adults with moderate-severe OSA (AHI 15–65), CPAP-intolerant, BMI <32–35, non-concentric palatal collapse on drug-induced sleep endoscopy (DISE), no significant central apneas

— Activated nightly via remote; STAR trial showed ~68% AHI reduction

— Adenotonsillectomy: first-line for pediatric OSA, occasionally helpful in adults with tonsillar hypertrophy

— UPPP (uvulopalatopharyngoplasty): modest response rates (~40%), largely supplanted

— Maxillomandibular advancement (MMA): highly effective in selected craniofacial candidates; near-CPAP equivalence

— Nasal surgery (septoplasty, turbinate reduction): adjunct to improve CPAP tolerance, not curative alone

— Strong consideration for BMI ≥35 with OSA; significant AHI reduction with sustained weight loss; reassess with repeat sleep study post-op

— Solriamfetol (DA/NE reuptake inhibitor) — caution in HTN, CVD

— Modafinil/armodafinil — reduces OCP efficacy, monitor BP

— Pitolisant (H3 inverse agonist) — QT prolongation caution

When CPAP fails despite optimization, escalate by phenotype and severity:

Mandibular advancement devices (MADs / oral appliances):

Hypoglossal nerve stimulator (Inspire):

Upper airway surgery:

Bariatric surgery:

Tracheostomy: reserved for severe OSA with life-threatening hypoxemia refractory to all therapy.

Pharmacotherapy for residual sleepiness on adequate CPAP:

Board pearl: Inspire is not appropriate for BMI 40 with AHI 50 — refer for bariatric surgery + CPAP instead. Know the BMI and AHI windows.

Step 3 management: CPAP-intolerant moderate OSA, BMI 28, fails MAD trial → refer to sleep surgery for DISE and hypoglossal nerve stimulator evaluation.

Special Populations — Elderly and Renal/Hepatic Impairment

— OSA prevalence rises with age; presentation often atypical — cognitive complaints, nocturia, falls, depression rather than classic sleepiness

— Untreated OSA in elderly associated with cognitive decline, worsening dementia trajectory, increased cardiovascular events

— CPAP improves cognition, mood, and nocturia; pursue treatment despite age

— Adherence barriers: arthritis (mask handling), cognitive impairment (require caregiver support), polypharmacy (sedatives worsen OSA)

— Avoid benzodiazepines, "Z-drugs," sedating antihistamines, opioids — these worsen OSA and increase fall risk (Beers list)

— OSA prevalence in dialysis patients ~50–70%; contributes to refractory HTN, LVH, sudden cardiac death

— Fluid shifts overnight (rostral fluid redistribution) worsen pharyngeal edema → OSA severity tracks volume status

— Nocturnal/long-hours hemodialysis or kidney transplant can substantially reduce AHI

— CPAP safe; titrate as usual; verify with sleep study post-transplant — AHI may improve dramatically

— OSA independently linked to NAFLD/NASH progression via intermittent hypoxia and oxidative stress

— Treat OSA aggressively in cirrhotics with daytime sleepiness — also rule out hepatic encephalopathy as competing cause

— Avoid sedating agents (benzos for HE, opioids for pain) when possible

— Both OSA and CSA common in HFrEF; adaptive servo-ventilation (ASV) is contraindicated in HFrEF with LVEF ≤45% and predominant central apnea (SERVE-HF: increased mortality)

— For OSA + HFrEF: CPAP is appropriate; for CSA + HFrEF: optimize GDMT first, consider nocturnal O₂

— Opioids cause central and ataxic breathing; consider in-lab PSG, not HSAT

— May need BiPAP-ST or ASV (if LVEF preserved); reduce opioid dose where feasible

Older adults (≥65):

Chronic kidney disease and ESRD:

Hepatic impairment / NAFLD:

Heart failure overlap:

Opioid users / chronic pain:

Step 3 management: Elderly patient on chronic zolpidem with new nocturnal confusion and witnessed apneas → stop the Z-drug, evaluate with in-lab PSG, treat OSA — do not add another sedative.

Board pearl: SERVE-HF made ASV contraindicated in symptomatic HFrEF (EF ≤45%) with predominant central apnea — high-yield safety question.

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— OSA prevalence rises in 3rd trimester due to weight gain, fluid retention, upper airway edema, diaphragmatic elevation

— Associated with gestational HTN, preeclampsia, gestational diabetes, preterm birth, low birth weight, C-section

— Screen any pregnant patient with snoring, witnessed apneas, obesity, chronic HTN, or preeclampsia history

— Diagnostic: HSAT or PSG safe in pregnancy

— Treatment: CPAP is first-line and safe throughout pregnancy; pressures may need to be increased as pregnancy progresses

— Postpartum: reassess with repeat sleep study after weight loss

— Peak incidence ages 2–8; primary cause is adenotonsillar hypertrophy

— Presentation differs from adults: hyperactivity, behavioral problems, poor school performance, enuresis, failure to thrive, mouth breathing, snoring — less classic daytime sleepiness

— Diagnosis: in-lab PSG (HSAT not validated in children); pediatric AHI ≥1 is abnormal

— First-line treatment: adenotonsillectomy

— Persistent OSA post-T&A (obesity, craniofacial syndromes, Down syndrome) → CPAP, weight loss, orthodontics, intranasal steroids/montelukast for mild residual disease

— OSA prevalence 50–80%; AAP recommends PSG by age 4 in all children with Down syndrome regardless of symptoms

— Loss of progesterone-driven upper airway tone increases OSA risk; HRT effect inconclusive

— Often present with insomnia/fatigue rather than overt sleepiness — easy to miss

— DOT/FAA require evaluation for STOP-BANG ≥3, BMI ≥35, or witnessed apnea

— Certification requires documented PAP adherence (≥4 h/night on ≥70% of nights) with objective download data

— STOP-BANG ≥3 → consider preop sleep evaluation for elective surgery

— Increased risk of postop respiratory failure, reintubation, ICU transfer, AF

— Use regional anesthesia where possible; minimize opioids; continuous SpO₂ monitoring; bring patient's own CPAP to the hospital

Pregnancy:

Pediatric OSA:

Down syndrome:

Postmenopausal women:

Commercial drivers / pilots:

Perioperative OSA:

Board pearl: Pediatric OSA → tonsils first, CPAP later. Adult OSA → CPAP first, surgery later.

Step 3 management: Pregnant patient at 32 weeks with snoring, BMI 38, BP 150/95 — order PSG/HSAT, start CPAP if confirmed, intensify preeclampsia surveillance.

Complications and Adverse Outcomes of Untreated OSA

— Systemic HTN, especially resistant and nocturnal non-dipping

— Atrial fibrillation — OSA doubles AF risk and increases recurrence after cardioversion/ablation by ~2×

— CAD/MI — increased event rates, particularly nocturnal MI

— Heart failure — both HFrEF and HFpEF; OSA worsens diastolic dysfunction

— Pulmonary hypertension — usually mild-moderate WHO Group 3; severe PH suggests OHS or other cause

— Stroke — independent risk factor; OSA prevalence ~60% post-stroke

— Sudden cardiac death — peak incidence shifts to nocturnal hours (midnight–6 AM) in OSA patients

— Insulin resistance, worsened glycemic control in T2DM, dyslipidemia, NAFLD/NASH

— Excessive daytime sleepiness, impaired attention/memory/executive function

— Depression, anxiety, reduced quality of life

— Possible acceleration of mild cognitive impairment → dementia

— 2–3× increased MVA risk; drowsy driving major source of preventable mortality

— Occupational injuries in commercial drivers, pilots, machinery operators

— Post-extubation airway obstruction, hypoxemic events, reintubation, postop AF, prolonged LOS, ICU transfer

— Nocturia, erectile dysfunction, GERD, glaucoma, floppy eyelid syndrome

— Secondary erythrocytosis from chronic hypoxemia (rule out OSA before workup for polycythemia in obese patients)

— Severe untreated OSA (AHI ≥30) associated with ~2–3× all-cause mortality over 10–15 years; CPAP appears to reduce mortality with good adherence (observational data; RCTs limited by adherence)

Cardiovascular:

Metabolic:

Neurocognitive and psychiatric:

Safety:

Perioperative:

Other:

Mortality:

Key distinction: OSA causes intermittent hypoxia/sympathetic surges (cardiovascular outcomes); OHS adds sustained hypercapnia and higher mortality, often with right heart failure on presentation.

Board pearl: New AF in an obese hypertensive man → screen for OSA; treating OSA improves ablation/cardioversion success.

Step 3 management: Polycythemia workup in obese man — before EPO/JAK2 testing, get a sleep study; OSA-induced erythrocytosis resolves with CPAP.

When to Escalate Care — Inpatient, ICU, and Consult Triggers

— Suspected obesity hypoventilation syndrome (OHS) with awake hypercapnia (PaCO₂ ≥45), hypoxemia (SpO₂ <90% awake), or cor pulmonale — admit for ABG, BiPAP initiation, diuresis

— Decompensated right heart failure attributable to OSA/OHS

— Severe nocturnal hypoxemia (SpO₂ <80% sustained) or arrhythmias on initial monitoring

— Post-op hypoxemic respiratory failure in known/suspected OSA

— Hypercapnic respiratory failure requiring NIV with hemodynamic instability or altered mental status

— Failed NIV requiring intubation

— Severe OSA + opioid overdose or sedative ingestion with airway compromise

— Sleep medicine — complex cases, suspected CSA, OHS, CPAP failure, evaluation for Inspire

— ENT — anatomic obstruction, surgical candidacy, evaluation for DISE

— Cardiology — resistant HTN, AF/HF management overlap

— Pulmonology — overlap COPD, hypoventilation, pulmonary HTN

— Bariatric surgery — BMI ≥35 with OSA as comorbidity

— Dental sleep medicine — MAD fitting

— Patient reports drowsy-driving crash or near-miss → counsel to stop driving until treated, document, expedite sleep testing and CPAP initiation; for CDL holders, notify per DOT regulations and state law

— Known OSA on CPAP undergoing elective surgery → bring CPAP to hospital, continuous postop SpO₂ monitoring, opioid-sparing analgesia, regional anesthesia preferred

— Unrecognized OSA with postop hypoxemia → expedited inpatient sleep evaluation before discharge

OSA is predominantly an outpatient diagnosis, but several scenarios mandate escalation:

Urgent/inpatient referral:

ICU triggers:

CCS pearl: For an obese patient admitted with somnolence and ABG showing pH 7.30/PaCO₂ 65/PaO₂ 55/HCO₃ 32: order BiPAP (start IPAP 12 / EPAP 6, titrate up), continuous SpO₂ and telemetry, ABG in 1–2 hours, CXR, TSH, BNP, echo, DVT prophylaxis, head of bed elevated, and avoid sedatives/opioids. Consult pulmonology/sleep medicine for inpatient titration and outpatient transition.

Specialist consults from clinic:

Driving safety escalation:

Perioperative escalation:

Step 3 management: Don't let an obese hypercapnic patient discharge without a clear plan: confirmed PAP setup at home (BiPAP if OHS), DME company arranged, follow-up with sleep medicine within 1–2 weeks, and primary care follow-up at 4 weeks.

Key Differentials — Same-Category Sleep-Disordered Breathing Causes

— Absent respiratory effort during apneas (flat thoracoabdominal belts)

— Causes: HFrEF (Cheyne-Stokes), opioids, stroke, high altitude, idiopathic, brainstem lesions

— Treat underlying cause; CPAP may help mild cases; ASV contraindicated in HFrEF EF ≤45%; consider BiPAP-ST, nocturnal O₂

— Begins as central, transitions to obstructive within same event; often improves with CPAP

— Central apneas appear after CPAP initiation in patient with initially pure OSA

— Often resolves with continued CPAP over weeks; persistent cases → ASV (if EF preserved) or BiPAP-ST

— BMI ≥30 + awake PaCO₂ ≥45 mmHg + no alternative cause; ~90% have coexistent OSA

— Treatment: BiPAP (preferred when severe hypercapnia or CPAP fails), weight loss, treat OSA

— Greater nocturnal hypoxemia, higher pulmonary HTN and mortality risk

— Treatment: CPAP + bronchodilators + supplemental O₂ if needed; BiPAP if hypercapnic

— Snoring + RERAs + daytime sleepiness with AHI <5 but elevated RDI

— Treat as OSA with CPAP or MAD if symptomatic

— ALS, muscular dystrophy, post-polio, diaphragmatic paralysis, chest wall disease

— Treatment: BiPAP-ST or volume-assured pressure support

— Crescendo-decrescendo respiration with central apneas; classic in advanced HF and stroke

— Optimize HF therapy first

Central sleep apnea (CSA):

Mixed sleep apnea:

Treatment-emergent central sleep apnea (TECSA / "complex sleep apnea"):

Obesity hypoventilation syndrome (OHS):

Overlap syndrome (OSA + COPD):

Upper airway resistance syndrome (UARS):

Nocturnal hypoventilation from neuromuscular disease:

Cheyne-Stokes respiration:

Key distinction: The single most important branch point on PSG is effort during apneas — present = obstructive; absent = central. This dictates whether CPAP alone suffices or you need BiPAP-ST/ASV/oxygen.

Board pearl: CPAP user develops new central apneas at follow-up → TECSA — continue CPAP, recheck in 2–3 months, escalate to ASV (if EF preserved) only if persistent.

Key Differentials — Other-Category Causes of Daytime Sleepiness

— Most common cause; <7 hours/night chronically; resolves with adequate sleep

— Diagnose by sleep diary or actigraphy

— Type 1 (with cataplexy, low CSF hypocretin) and Type 2

— Classic tetrad: EDS, cataplexy, sleep paralysis, hypnagogic hallucinations

— Diagnosis: PSG followed by MSLT showing mean sleep latency <8 min and ≥2 SOREMPs

— Treatment: modafinil/armodafinil, solriamfetol, pitolisant, sodium oxybate; SNRIs for cataplexy

— Long unrefreshing sleep, severe sleep inertia, MSLT <8 min without SOREMPs

— Uncomfortable urge to move legs at rest, relieved by movement; check ferritin (target >75–100); treat iron deficiency, dopamine agonists/gabapentinoids

— Shift-work disorder, delayed sleep phase, jet lag

— Treat with bright light, melatonin timing, behavioral measures

— Sedating antihistamines, benzodiazepines, opioids, antipsychotics, gabapentin, alcohol

— Caffeine/stimulant withdrawal

— Hypothyroidism (check TSH), anemia, CHF, depression (atypical with hypersomnia), chronic fatigue syndrome, uncontrolled diabetes

— Postconcussive syndrome, multiple sclerosis, Parkinson disease

— Difficulty initiating/maintaining sleep → daytime fatigue (not true sleepiness); first-line CBT-I, not hypnotics

Not every sleepy patient has OSA — differential of excessive daytime sleepiness (EDS):

Insufficient sleep syndrome:

Narcolepsy:

Idiopathic hypersomnia:

Restless legs syndrome / periodic limb movement disorder:

Circadian rhythm disorders:

Medications and substances:

Medical causes mimicking OSA:

Insomnia disorder:

Key distinction: Fatigue (tiredness without falling asleep) ≠ sleepiness (tendency to actually fall asleep). Narcolepsy and OSA cause true sleepiness; depression and fibromyalgia more often cause fatigue.

Board pearl: Young patient (teens-20s) with sleep attacks + cataplexy with laughter → narcolepsy type 1, not OSA; order PSG + MSLT.

Step 3 management: Sleepy patient with normal STOP-BANG, normal BMI, normal exam — get TSH, CBC, depression screen, sleep diary, and consider PSG/MSLT for narcolepsy before assuming OSA.

Secondary Prevention and Long-Term Plan

— Lifelong therapy unless anatomic/weight changes resolve disease (confirm with repeat sleep study)

— Replace supplies on schedule: masks q3 months, cushions q1 month, tubing q3 months, filters monthly, humidifier chamber q6 months, device q5 years

— Annual review of adherence data, residual AHI, leak, symptoms

— HTN: ambulatory BP monitoring if resistant; CPAP plus standard antihypertensives; spironolactone often added for resistant HTN

— AF: rhythm control success higher in treated OSA; integrate with cardiology

— DM/obesity: weight loss program, dietitian, consider GLP-1/GIP agonists (semaglutide, tirzepatide), bariatric surgery for BMI ≥35

— Dyslipidemia: statin per ASCVD risk

— Mood: screen for depression (PHQ-9) annually

— Sustained weight loss (5–10% can meaningfully reduce AHI)

— Alcohol minimization, avoidance within 3 hours of sleep

— Avoid benzodiazepines, opioids, sedating antihistamines

— Sleep hygiene: consistent schedule, 7–9 hours, dark/cool environment

— Positional therapy if positional component documented

— Annual influenza, age/risk-appropriate pneumococcal (PCV20 or PCV15+PPSV23), COVID-19 updates, RSV per ACIP

— Significant weight change (≥10%)

— Recurrence of symptoms despite documented adherence

— After major upper airway surgery, MAD fitting, or bariatric surgery

— After cardiac event or new arrhythmia

— Patient request to discontinue CPAP (objective documentation needed)

OSA is a chronic disease; long-term management mirrors HTN or DM in cadence and intensity.

Core long-term CPAP plan:

Comorbidity co-management:

Lifestyle reinforcement:

Vaccinations:

Repeat sleep testing indicated when:

CCS pearl: Maintain a problem list that explicitly carries "OSA on CPAP" so every clinician treating the patient avoids sedating prescriptions and reinforces adherence.

Board pearl: Bariatric surgery patient 1 year post-op with 35% weight loss — order repeat PSG before discontinuing CPAP; symptom resolution alone is not enough to stop therapy.

Follow-Up, Monitoring Parameters, and Counseling

— 2–4 weeks: troubleshoot mask, pressure, side effects, review adherence download

— 30–90 days: confirm Medicare/insurance adherence criteria (≥4 h/night, ≥70% of nights), document clinical benefit

— 6 months: reassess symptoms, adherence, residual AHI, weight, BP

— Annually thereafter: download review, comorbidity check, supply replacement, vaccinations

— Adherence data: nightly usage hours, % of nights ≥4 h, residual AHI, mask leak

— Goal: residual AHI <5, leak within device threshold, usage ≥6 h/night ideally (more is better)

— Symptoms: ESS, sleep quality, partner report, nocturia, morning headaches

— BP, weight, BMI, A1c, lipids per comorbidity

— Side effects: dry mouth, aerophagia, skin breakdown, claustrophobia

— Driving safety: caution against driving when sleepy; commercial drivers must meet adherence criteria for certification

— Weight management: structured program, dietitian, exercise prescription, consider pharmacotherapy/bariatric surgery

— Substance avoidance: alcohol, sedatives, opioids

— Travel: CPAP qualifies as medical device for air travel; portable battery options; humidifier without water for flights

— Bed partner: include in education; partner-reported snoring/apneas useful clinical signal

— Annual BP, fasting lipids, A1c

— Repeat echo if pulmonary HTN or RV dysfunction at baseline

— AF screening if symptoms or history

— CBT-I if coexisting insomnia (very common, undertreated)

— Smoking cessation, structured exercise

— Peer support groups, telemedicine sleep follow-up

Visit cadence after CPAP initiation:

What to monitor at each visit:

Counseling priorities (longitudinal):

Cardiac and metabolic surveillance:

Rehab/behavioral support:

Step 3 management: At 6-month visit, CPAP adherence 7.5 h/night, residual AHI 2, but persistent ESS 14 — check sleep duration (insufficient sleep), screen for depression, check ferritin/TSH, and consider wake-promoting agent (modafinil/solriamfetol) for residual EDS.

Board pearl: Residual AHI on download >10 despite good adherence → mask leak, inadequate pressure, or emergent central apneas — re-titrate or order PSG.

Ethical, Legal, and Patient Safety Considerations

— Physicians must counsel OSA patients about drowsy-driving risk and document the conversation

— Commercial drivers (CDL): FMCSA/DOT guidelines require evaluation when STOP-BANG suggests OSA; certification requires documented CPAP adherence (≥4 h/night on ≥70% of nights over 30 days) verified by device download

— Mandatory reporting of unsafe drivers varies by state — California, Oregon, Pennsylvania, Nevada, New Jersey, and Delaware require physician reporting of conditions impairing driving; most other states permit but do not require it

— Pilots, train engineers: notify per FAA/FRA medical certification requirements

— Surgical interventions (UPPP, MMA, Inspire, bariatric surgery): discuss realistic AHI reduction, alternatives (CPAP, MAD), risks (bleeding, dysphagia, persistent OSA), need for postoperative sleep study

— Inspire: implantable device, MRI conditional, battery replacement at ~11 years — disclose

— Pediatric adenotonsillectomy: parental consent; explain that obesity-associated pediatric OSA may persist post-T&A

— Patients with undiagnosed or untreated OSA undergoing surgery have elevated perioperative respiratory events

— Step 3 transition-of-care item: Always communicate OSA status (and CPAP settings) to surgical/anesthesia teams; ensure patient brings CPAP to hospital and resumes immediately postop; avoid PCA-only opioid regimens without continuous SpO₂/capnography monitoring

— CMS and most private payers require objective adherence data (≥4 h/night on ≥70% of nights) within 90 days to continue coverage — patients must be educated on this upfront to avoid losing coverage

— Document residual symptoms and clinical benefit at the 30–90 day follow-up

— A patient who refuses to stop driving despite documented severe untreated OSA with recent drowsy-driving crash creates a duty-to-warn dilemma; counsel, document refusal, escalate per state law and institutional policy

— Sleep testing access, CPAP affordability, and DME availability vary widely; advocate for HSAT where appropriate and connect with social work for equipment access

Driving safety and reporting:

Informed consent edge cases:

Perioperative safety (transition-of-care risk):

Insurance and access:

Confidentiality vs safety:

Health equity:

Board pearl: A truck driver with AHI 45 who insists on returning to work without CPAP — counsel, document, and notify per DOT/state law; certification cannot be issued without documented adherence.

Step 3 management: Always document the driving counseling conversation in the EHR — it is both ethically and legally protective.

High-Yield Associations and Rapid-Fire Clinical Facts

OSA + resistant HTN → screen all; CPAP modestly lowers BP, more in non-dippers.

OSA + AF → treating OSA improves cardioversion and ablation success.

OSA + HFrEF → treat OSA with CPAP; if central apnea predominates and EF ≤45%, ASV is contraindicated (SERVE-HF).

OSA + stroke/TIA → prevalence ~60%; treat to reduce recurrence risk.

OSA + T2DM → worsens insulin resistance; CPAP modestly improves glycemia.

OSA + erectile dysfunction/nocturia/GERD → all improve with CPAP.

OSA + glaucoma / floppy eyelid syndrome → known associations.

OSA + secondary erythrocytosis → check sleep study before extensive heme workup.

Pediatric OSA → adenotonsillectomy first; behavioral problems often the presenting feature.

Down syndrome → screening PSG by age 4 regardless of symptoms.

Pregnancy + snoring + HTN → think OSA; CPAP safe; reduces preeclampsia risk.

Bariatric surgery candidate → screen for OSA preop; reassess with repeat PSG postop.

Obesity hypoventilation syndrome → BMI ≥30 + awake PaCO₂ ≥45; BiPAP preferred over CPAP when severe hypercapnia or CPAP fails.

Overlap syndrome (OSA + COPD) → higher pulmonary HTN and mortality; CPAP ± O₂.

STOP-BANG: ≥3 intermediate, ≥5 high risk.

AHI thresholds: 5–14 mild, 15–29 moderate, ≥30 severe.

CPAP adherence (CMS): ≥4 h/night, ≥70% of nights, over 30 consecutive days within first 90 days.

HSAT contraindications: significant cardiopulmonary disease, suspected CSA/OHS, neuromuscular disease, opioids, stroke, children.

MSLT → narcolepsy diagnostics (sleep latency <8 min, ≥2 SOREMPs).

Inspire (HGNS) indications: AHI 15–65, CPAP-intolerant, BMI <32–35, non-concentric collapse on DISE.

Drugs that worsen OSA: alcohol, benzodiazepines, opioids, "Z-drugs", sedating antihistamines, muscle relaxants.

Wake-promoting agents for residual EDS on adequate CPAP: modafinil, armodafinil, solriamfetol, pitolisant.

GLP-1/GIP agonists (tirzepatide, semaglutide) → emerging adjunctive OSA therapy via weight loss.

Board pearl: Two reflex Step 3 moves — resistant HTN → screen OSA, and new AF in obese male → screen OSA.

Step 3 management: Memorize STOP-BANG, AHI cutoffs, CPAP adherence rule, and SERVE-HF/ASV contraindication — these recur across question stems.

Board Question Stem Patterns

Stem 1 — Classic OSA: Obese man, BMI 36, loud snoring, witnessed apneas, ESS 16, resistant HTN on 3 drugs. Best next step? → HSAT or in-lab PSG (not empiric CPAP, not Epworth alone, not weight-loss-only counseling).

Stem 2 — Pediatric OSA: 6-year-old with snoring, hyperactivity, enuresis, tonsils 3+. Best next step? → PSG, then adenotonsillectomy if confirmed.

Stem 3 — Resistant HTN: BP uncontrolled on ACEi + amlodipine + HCTZ. Next test? → screen for OSA (and primary aldosteronism); ambulatory BP monitor.

Stem 4 — New AF: Obese man with new AF and snoring; failed cardioversion. Best next step to improve rhythm control? → diagnose and treat OSA.

Stem 5 — Pregnancy + preeclampsia history: 32-week pregnant patient, snoring, BP 150/95. Next step? → sleep testing; if OSA, CPAP.

Stem 6 — OHS: BMI 45, somnolent, ABG pH 7.32/PCO₂ 60/HCO₃ 32. Treatment? → BiPAP, not CPAP alone; weight loss, sleep medicine referral.

Stem 7 — SERVE-HF: HFrEF EF 30%, predominant central apneas. Contraindicated therapy? → ASV.

Stem 8 — TECSA: Patient on CPAP develops central apneas at 1 month. Best step? → continue CPAP, reassess in 2–3 months.

Stem 9 — Pediatric Down syndrome: Age 4, no overt symptoms. Next step? → screening PSG.

Stem 10 — Secondary erythrocytosis: Obese man with Hb 19, normal EPO. Next step? → sleep study before JAK2 testing.

Stem 11 — Residual sleepiness on adequate CPAP: Adherence 7 h, residual AHI 3, ESS 14. Next step? → check sleep duration, TSH, depression, ferritin; if all negative, add modafinil/solriamfetol.

Stem 12 — Commercial driver: CDL driver with witnessed apneas. Management? → expedited evaluation, treat, document adherence before recertification.

Stem 13 — Postop hypoxemia: Known OSA, post-cholecystectomy desaturating on PCA morphine. Next step? → reduce opioid, restart CPAP, continuous SpO₂, consider naloxone if severe.

Stem 14 — CPAP failure, BMI 28, AHI 22: Next options? → MAD trial; if fails, evaluate for hypoglossal nerve stimulator.

Board pearl: When a stem describes "loud snoring + witnessed apneas + daytime sleepiness + hypertension," the single best next step is almost always objective sleep testing — not empiric CPAP, not weight-loss-only counseling, not modafinil.

Step 3 management: Read the stem for comorbidities — they dictate HSAT vs PSG, and CPAP vs BiPAP.

One-Line Recap

— Screen by case-finding, not universally — USPSTF says insufficient evidence to screen asymptomatic adults; pursue testing in resistant HTN, AF, HFpEF/HFrEF, stroke, T2DM, refractory sleepiness, or STOP-BANG ≥3 with symptoms.

— Diagnose with HSAT or PSG; AHI ≥15 alone or AHI 5–14 with symptoms/comorbidity confirms OSA; use in-lab PSG if cardiopulmonary disease, suspected central apnea, OHS, neuromuscular disease, opioids, or pediatric.

— Treat moderate-severe (AHI ≥15) with CPAP first; add weight loss, alcohol/sedative avoidance, positional therapy; escalate to MAD, hypoglossal nerve stimulation, surgery, or bariatric surgery for CPAP failure/intolerance; BiPAP for OHS, ASV contraindicated in HFrEF EF ≤45% with central apnea.

— Follow up with adherence downloads (≥4 h/night, ≥70% nights), monitor residual AHI, manage cardiometabolic comorbidities, counsel on drowsy-driving safety (with mandatory reporting in select states and DOT/FAA implications), and repeat sleep testing after significant weight change or symptom recurrence.

In one sentence: Obstructive sleep apnea is a chronic, underdiagnosed cause of cardiometabolic, cognitive, and accident-related morbidity that you diagnose with case-finding plus objective sleep testing (HSAT in uncomplicated high-probability adults, in-lab PSG otherwise) and treat with CPAP as first-line, integrated with lifelong weight, comorbidity, safety, and adherence management.

High-yield recap bullets:

Final board pearl: When in doubt on Step 3 — objective sleep testing first, CPAP first, document adherence and driving counseling always.